| Cite this article: |
| SUN Limin,ZENG Kun,ZHANG Zhen,MU Yuejing,ZHAO Zhenzhen,HAN Ying.Exploration of "Three-in-One" collaborative inspection model for pharmaceuticals[J].Journal Of Pharmaceutical Research,2026,45(6):716-720[Click to copy] |
|
| 摘要: |
| 目的 探索药品监管协同检查新模式,提升监管效能、优化检查资源配置、减轻企业负担,为完善药品监管体系、推动医药产业高质量发展提供实践参考。方法 回顾2023 年2月以来山东省在药品上市后变更备案领域推行 “三合一”检查的实践历程,以检查资源优化成效、检查员队伍能力提升为核心评价指标,系统总结该模式在机制构建、流程创新及队伍建设等方面的实施经验。结果与结论 通过制度完善、流程优化及全流程风险管控等关键举措,“三合一” 检查模式有效提升了检查资源配置效率,显著增强了检查员队伍综合能力,为药品监管协同化发展提供了可复制的实践路径,对提升药品监管质效、赋能产业高质量发展具有重要实践价值。 |
| 关键词: 药品监管 协同检查 监管效能 |
| DOI:10.13506/j.cnki.jpr.2026.06.017 |
| 基金项目: |
|
Received Date:October 24, 2025
Revision Date:January 28, 2026
|
|
| Exploration of "Three-in-One" collaborative inspection model for pharmaceuticals |
| SUN Limin,ZENG Kun,ZHANG Zhen,MU Yuejing,ZHAO Zhenzhen,HAN Ying |
| (Shandong Center for Food and Drug Evaluation & Inspection,Jinan 250014,China) |
| Abstract: |
| Objective To explore a novel model for collaborative drug regulatory inspections, with the aim of enhancing regulatory efficiency, optimizing the allocation of inspection resources, alleviating the burden on enterprises, and providing practical references for improving the drug regulatory system and promoting high-quality development of the pharmaceutical industry.Methods This study reviews the practical implementation of the "tripartite integrated inspection" model in the field of post-approval change filings in Shandong Province since February 2023. Focusing on the optimization of inspection resources and the enhancement of inspector competencies as core evaluation indicators, it systematically summarizes the implementation experience of this model in terms of mechanism establishment, process innovation, and team development.Results and Conclusion Through key measures such as institutional refinement, process optimization, and comprehensive risk management throughout the inspection cycle, the "tripartite integrated inspection" model has effectively improved the efficiency of inspection resource allocation and significantly strengthened the comprehensive capabilities of the inspection team. This model provides a replicable practical pathway for the collaborative development of drug regulation and holds significant practical value for enhancing the quality and effectiveness of drug oversight and empowering the high-quality development of the industry. |
| Key words: Drug regulation Collaborative inspection Regulatory efficiency |